72 completed, 34 recruiting, 22 active not recruiting, 20 terminated. 61 Phase 2, 28 Phase 1, 20 Not applicable, 18 Phase 3, 5 Early Phase 1.
Follow Hypergammaglobulinemia: new trials by email Literature Review of Hypergammaglobulinemia trials Research Report on Hypergammaglobulinemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Evaluating the Impact of a 12-month Multi-Modal Lifestyle Management Intervention on Disease Relevant Biomarkers The Multimodal Lifestyle Intervention - Monoclonal Gammopathy of Uncertain Significance, Smoldering Myeloma | Not applicable | Not yet recruiting | Hackensack Meridian Health | 67 | 2026-10-01 | 2026-08-24 |
| Early Detection of Amyloidosis in Monoclonal Gammopathy Using Nuclear Medicine Imaging ¹⁸F-florbetaben - Monoclonal Gammopathy, Monoclonal Gammopathy of Undetermined Significance (MGUS) | Not applicable | Not yet recruiting | University of Zurich | 50 | 2026-10-01 | 2026-06-03 |
| Early Screening for Multiple Myeloma Based on Liquid Biopsy cfDNA Fragmentomics Multiple Myeloma (MM), Smoldering Multiple Myeloma (SMM) | Not yet recruiting | The First Affiliated Hospital with Nanjing Medical University | 290 | 2026-06-13 | 2026-07-06 | |
| A Study to Compare Linvoseltamab and Daratumumab Treatment in High-Risk Smoldering Multiple Myeloma (HR-SMM) Linvoseltamab, Daratumumab - High Risk Smoldering Multiple Myeloma (HR-SMM) | Phase 3 | Recruiting | Regeneron Pharmaceuticals | 270 | 2026-05-21 | 2026-10-21 |
| FAST-M: Prolonged Overnight Fasting and Mediterranean Dietary Intervention for Patients With Multiple Myeloma or Its Precursor Disease Health Coaching, Prolonged Overnight Fasting (POF), Mediterranean Diet - Multiple Myeloma, Monoclonal Gammopathy of Undetermined Significance | Not applicable | Recruiting | University of Miami | 120 | 2026-04-07 | 2026-05-01 |
| Clonal Hematopoiesis of Immunological Significance observational cohort study - Immune System Diseases, Autoimmune Diseases | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 5000 | 2026-04-01 | 2026-03-23 | |
| Exploring the Effects of Korean-Style Mediterranean Diet (KORMED) and Physical Activity Measurement in Patients With MGUS/SMM: A Pilot Study KORMED Diet and Physical Activity Monitoring - Monoclonal Gammopathy of Undetermined Significance, Smoldering Myeloma | Not applicable | Not yet recruiting | Seoul National University Bundang Hospital | 20 | 2026-01-30 | 2026-01-21 |
| A Prospective Multicenter Study of the Effects of Plant-based Diets on Gut Microbiome and Derived Metabolites in Patients Affected by Smoldering Multiple Myeloma diet rich in fiber - Smoldering Multiple Myeloma (SMM) | Not applicable | Recruiting | Ciceri Fabio | 62 | 2025-10-31 | 2026-04-03 |
| Determine the Frequency of Variants in the GBA/PSAP Genes in Patients With MM or MGUS Evaluation of the presence and number of mutated alleles of the GBA/PSAP genes in patients with MM or MGUS - Monoclonal Gammopathy of Undetermined Significance, Myeloma Multiple | Recruiting | University Hospital, Rouen | 300 | 2025-10-07 | 2026-06-10 | |
| Daratumumab for Polyneuropathy Associated With MGUS Daratumumab and hyaluronidase-fihj - Peripheral Neuropathy, Monoclonal Gammopathy of Undetermined Significance | Phase 2 | Withdrawn | Georgetown University | 2025-09-26 | 2025-10-01 | |
| Isatuximab and Iberdomide as Immunotherapy for High Risk in Smouldering Myeloma Isatuximab, Iberdomide, Dexamethasone - Smouldering Myeloma | Phase 2 | Recruiting | University College, London | 63 | 2025-06-02 | 2026-10-20 |
| Ilaris NIS in Korea Ilaris - Hereditary Periodic Fever Syndromes, Cryopyrin-associated Periodic Syndromes (CAPS) | Recruiting | Novartis Pharmaceuticals | 25 | 2025-03-29 | 2026-05-19 | |
| Integrative Multi-omics Analysis to Predict Monoclonal Gammopathies Clinical Evolution Collection of biological material - Monoclonal Gammopathy of Undetermined Significance (MGUS), Smoldering Multiple Myeloma (SMM) | Recruiting | Azienda USL Reggio Emilia - IRCCS | 60 | 2025-03-17 | 2026-04-23 | |
| CHAAMP (CHArlotte Advocate MGUS Project) Internal Pilot Study Blood draw for the laboratory assessment - Multiple Myeloma, Multiple Myeloma Progression | Recruiting | Wake Forest University Health Sciences | 1665 | 2025-03-01 | 2026-07-13 | |
| A Study of Carbon 13-based Deep Labelling of Bone Marrow Cells Non-Interventional Study - Monoclonal Gammopathy of Undetermined Significance (MGUS), Non-IgM Monoclonal Gammopathy of Undetermined Significance | Enrolling by invitation | Mayo Clinic | 40 | 2025-02-01 | 2025-12-19 | |
| Characteristics and Clinical Significance of Gut Microbiota in Patients With Monoclonal Gammopathy Monoclonal Gammopathy of Undetermined Significance (MGUS), Intestinal Flora | Recruiting | Zhujiang Hospital | 2990 | 2024-12-26 | 2024-12-27 | |
| A Study of JNJ-79635322 in Combination With Daratumumab With or Without Lenalidomide for Multiple Myeloma, Newly Diagnosed AL Amyloidosis, and High-risk Smoldering Multiple Myeloma or JNJ-79635322 in Combination With Pomalidomide for Multiple Myeloma JNJ-79635322, Daratumumab, Pomalidomide - Multiple Myeloma, Smoldering Multiple Myeloma | Phase 1 | Recruiting | Janssen Research & Development, LLC | 276 | 2024-12-04 | 2026-09-25 |
| A Proof-of-Concept Study to Learn Whether Linvoseltamab Can Eliminate Abnormal Plasma Cells That May Lead to Multiple Myeloma in Adult Patients With High-Risk Monoclonal Gammopathy of Undetermined Significance or Non-High-Risk Smoldering Multiple Myeloma Linvoseltamab - Monoclonal Gammopathy of Undetermined Significance (MGUS), Smoldering Multiple Myeloma (SMM) | Phase 2 | Recruiting | Regeneron Pharmaceuticals | 116 | 2024-09-16 | 2026-07-08 |
| Screening for Monoclonal Gammopathy in Individuals Undergoing Physical Examinations Using iMS-LC Assay Technology. M protein detection by iMS-LC Assay - M Protein, Monoclonal Gammopathy | Unknown | Jian Li | 15600 | 2024-07-01 | 2024-07-09 | |
| A Real-world Study in Participants With Smoldering Multiple Myeloma Smoldering Multiple Myeloma | Completed | Janssen-Cilag Ltd. | 408 | 2024-05-31 | 2026-07-06 |
Showing 20 of 175. Sign in to see all of them.
Monoclonal Gammopathy of Undetermined Significance (100) · Multiple Myeloma (99) · Smoldering Multiple Myeloma (99) · Neoplasms, Plasma Cell (51) · Immunoglobulin Light-chain Amyloidosis (46) · Waldenstrom Macroglobulinemia (44) · Leukemia, Lymphocytic, Chronic, B-Cell (43) · Lymphoma, Follicular (40) · Lymphoma, Large B-Cell, Diffuse (40) · Lymphoma, Mantle-Cell (40) · Lymphoma, Non-Hodgkin (40) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (40) · Burkitt Lymphoma (39) · Lymphoma, Large-Cell, Immunoblastic (39) · Precancerous Conditions (39)
Hemic and Lymphatic Diseases (175) · Blood Protein Disorders (174) · Immunoproliferative Disorders (174) · Hematologic Diseases (173) · Immune System Diseases (172) · Paraproteinemias (158) · Neoplasms (153) · Neoplasms by Histologic Type (116) · Cardiovascular Diseases (102) · Hemorrhagic Disorders (102) · Hemostatic Disorders (102) · Vascular Diseases (102) · Precancerous Conditions (99) · Lymphoproliferative Disorders (97)
Lenalidomide (18) · Dexamethasone (15) · Calcium Dobesilate (8) · daratumumab (8) · Cyclophosphamide (6) · Peripheral Blood Stem Cell Transplantation (6) · Bortezomib (4) · Melphalan (4) · auricularum (4) · carfilzomib (4) · dexamethasone 21-phosphate (4) · dexamethasone acetate (4) · fludarabine phosphate (4) · Biopsy (3) · Curcumin (3)
Dana-Farber Cancer Institute (10) · Mayo Clinic (9) · National Cancer Institute (NCI) (9) · M.D. Anderson Cancer Center (6) · Memorial Sloan Kettering Cancer Center (6) · City of Hope Medical Center (5) · European Organisation for Research and Treatment of Cancer - EORTC (4) · Janssen Research & Development, LLC (4) · Novartis Pharmaceuticals (4) · Assistance Publique - Hôpitaux de Paris (3) · Barbara Ann Karmanos Cancer Institute (3) · Case Comprehensive Cancer Center (3) · Indiana University (3) · Jonsson Comprehensive Cancer Center (3) · Northwestern University (3)
United States (124) · France (17) · Italy (14) · United Kingdom (11) · Belgium (9) · Germany (9) · Spain (9) · Netherlands (8) · Czechia (6) · Israel (6) · Switzerland (5) · Turkey (Türkiye) (5) · Australia (4) · China (4) · Norway (4)
Irene Ghobrial, MD (5) · John A. Glaspy, MD, MPH (3) · Urvi A Shah, MD, MS (3) · Brea Lipe (2) · Mark J Roschewski, M.D. (2) · Michael A Rosenzweig (2) · Noopur Raje, MD (2) · Richard K. Burt, MD (2) · A. Broijl (1) · Ajai Chari, MD (1) · Ajay Nooka, MD (1) · Alex A. Adjei, MD, PhD (1)
PMID 15459300, PMID 16710026, PMID 17397698, PMID 19170225, PMID 19841031, PMID 20307284, PMID 20473362, PMID 22480131, PMID 22511492, PMID 22571201, PMID 23358983, PMID 23902483, PMID 24045500, PMID 24144643, PMID 24658821, PMID 26468228, PMID 26668134, PMID 26690712, PMID 26853648, PMID 27020837, PMID 27402145, PMID 28158311, PMID 28482144, PMID 28826616, PMID 30128502, PMID 30562587, PMID 31405950, PMID 31593552, PMID 31598151, PMID 31652094, PMID 32024950, PMID 32427579, PMID 32816893, PMID 33308307, PMID 33474705, PMID 36067617, PMID 36747117, PMID 36999619, PMID 37439374, PMID 38466984, PMID 38560901, PMID 38652812, PMID 38699307, PMID 38988266, PMID 39038268, PMID 39652675, PMID 39652826, PMID 39753553, PMID 40681960, PMID 41100731
P30CA015083 (4), 2023 (3), P30CA022453 (3), U10CA032102 (3), 2014 (2), 2016 (2), U10CA180820 (2), 2009 (1), 2017 (1), 2018 (1), 2025 (1), K22CA251648 (1), K23CA218742 (1), P30CA006973 (1), P30CA016058 (1)